FGAM
ALNY icon

Financial Gravity Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Financial Gravity Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5
Closed -$830 – 1459
2024
Q1 		$830 Buy
+5
New +$834 ﹤0.01% 1275
2023
Q3 		– Sell
-190
Closed -$132 – 1255
2023
Q2 		$132 Buy
+190
New +$37.7K ﹤0.01% 1258

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Financial Gravity Asset Management's ALNY Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2024, closing a stake of 5 shares — an estimated $830 sold.

Financial Gravity Asset Management first reported a position in ALNY in Q2 2023 and held it in 2 quarters. The position peaked at $830 in Q1 2024. 521 funds tracked by Wall St. Rank hold ALNY as of Q2 2024.

  • Financial Gravity Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Financial Gravity Asset Management sold 5 Alnylam Pharmaceuticals shares in Q2 2024, an estimated $830.
  • Financial Gravity Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Financial Gravity Asset Management's Alnylam Pharmaceuticals position peaked at $830 in Q1 2024.
  • 521 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.